Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial.
Mattioli C, Olmetto E, Banini M, Garlatti P, Caini S, Riccio MD, Finocchiaro G, Borghetti P, Pilotto S, Metro G, Grossi F, Farina G, Meriggi F, Chella A, Roca E, Zannori C, Delmonte A, Russo A, Macerelli M, Genova C, Cortinovis D, D'Arcangelo M, Del Conte A, Lugini A, Petrelli F, Vasile E, Iannopollo M, Taveggia PA, Quaquarini E, Baldini E, Ponzanelli A, Manzoni M, Cergnul M, Camerini A, Tartarone A, Inno A, Favaretto A, Veccia A, La Torre L, Perna M, Livi L, Bruni A, Scotti V.
Mattioli C, et al. Among authors: petrelli f.
Cancer Treat Res Commun. 2026 Feb 7;47:101132. doi: 10.1016/j.ctarc.2026.101132. Online ahead of print.
Cancer Treat Res Commun. 2026.
PMID: 41707549
Free article.